Nataliya Uboha, MD
University of Wisconsin, Madison
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Nataliya Uboha, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:52 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06048133 · Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)Nataliya Uboha · active not recruiting · Biliary Tract Carcinoma, Cholangiocarcinoma, Bile Duct Cancer · principal investigator
- Ph2NCT04150640 · Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric AdenocarcinomaUniversity of Wisconsin, Madison · recruiting · Esophageal Adenocarcinoma, Gastric Adenocarcinoma · principal investigator
- Ph2NCT03997448 · Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149Nataliya Uboha · terminated · Gastroesophageal Cancer, Adenocarcinoma · principal investigator
- Ph1NCT02943733 · Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETsUniversity of Wisconsin, Madison · terminated · Neuroendocrine Tumors, Neoplasms, Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:52 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.